Update on PCSK9 Inhibitors

WEBINAR

Update on PCSK9 Inhibitors

Faculty: Michael Shapiro, Seth Martin, Stephen Kopecky, Seth Baum

Notification icon This webinar took place on 
http://www.vumedi.com/webinar/update-on-pcsk9-inhibitors/

Program

Michael Shapiro

Oregon Health & Science University, Portland, OR.

Current Challenges in Lipid Lowering Therapy and Prevention of ASCVD

Seth Martin

Johns Hopkins School of Medicine, Baltimore, MD.

Science of PCSK9 and LDL-C Lowering Efficacy

Stephen Kopecky

Mayo Clinic, Rochester, MN.

CV Outcomes Trials with PCSK9 Inhibitors – SPIRE, ODYSSEY, FOURIER and EBBINGHAUS

Seth Baum

Barriers to Accessing PCSK9 Inhibitors

Faculty:

  • Michael Shapiro

    Oregon Health & Science University, Portland, OR.

  • Seth Martin

    Johns Hopkins School of Medicine, Baltimore, MD.

  • Robert Rosenson

    Mount Sinai Icahn School of Medicine, New York, NY.

  • Stephen Kopecky

    Mayo Clinic, Rochester, MN.

  • Seth Baum

    Miller School of Medicine, Miami, FL.

Release: 10/01/2018

Expiration: 09/30/2019

Location: Online

Requirements for successful completion: In order to receive credit, participants must view all audio-visual presentations and complete both the pre-test, post-test and evaluation form. Participants must score at least 100% on the activity post-test in order to receive credit. There are no pre-requisites for this activity. Course attendance verification forms are provided upon successful completion of the post-test and evaluation form. No partial credit will be given.

A planning committee made up of medical professionals and VuMedi, Inc. teamed up to create in-person and online trainings utilizing experts, peer-reviewed literature, and research to help educate physicians on the ever-changing therapeutic landscape in medicine. By clicking on the video link, you may view the 4-5 presentations in this video series. After viewing the videos, you may access the Evaluation link to earn CME Credit and receive your certificate.

California Assembly Bill 1195: This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME website at http://www.meded.uci.edu/CME/.

Disclaimer: The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine and VuMedi, Inc. Viewers should verify all information and data before treating patients or employing any therapies described in this educational activity. Healthcare professionals should use their clinical judgements in weighing possible risks and benefits before employing any treatment discussed in this activity.

Target Audience: This activity was developed for MD and Allied Health Professionals in the following Specialties: Cardiovascular.

Course Description: In this recorded webinar, expert Interventional Cardiology, Preventive Cardiology, Vascular Medicine, Non-Invasive Cardiovascular Imaging, Electrophysiology, General Adult Cardiology will present optimal operable techniques and treatment options to address Update on PCSK9 Inhibitors.

Learning Objectives: Upon completion of this activity, participants should be better able to discuss:

Credits: This lecture qualifies for 1 CME credit hour.

Cost: $0.0

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and VuMedi, Inc. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement: The University of California, Irvine School of Medicine designates this enduring materials for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures: The Directors, Speakers, Moderators, Planners, and Coordinators of this activity have no relevant financial relationships to disclose, except:

Dr. Seth Baum: Amgen Speakers Bureau, Advisor or Review Panel Member, Consultant, Honorarium Recipient, Regeneron, Advisor or Review Panel Member, Consultant, Honorarium Recipient, Sanofi, Advisor or Review Panel Member, Consultant, Honorarium Recipient Cleveland Heart Lab, Consultant, Honorarium Recipient, Akcea, Speakers Bureau, Advisor or Review Panel Member, Consultant, Honorarium Recipient.

Dr. Michael Shapiro: Advisor for GE Healthcare, Bracco, Alecion, Amgen and Akcea

Dr. Stephen Kopecky: Task force Member - no compensation for Mayo Clinic P&T Task, Research Grant/Support for True Health and Amgen, Consulting for Prime Therapeutics.

Dr. Seth Martin: Advisory Board Member for Quest, Sanofi/Regeneron and Amgen, Research Support for Apple and Google.

UCI OCME requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity, and promote improvements or quality in healthcare. It is the policy of the UCI Office of Continuing Medical Education to insure balance, independence , objectivity, and scientific rigor in all its educational activities. All faculty participating in UCI provided CME programs are expected to disclose to the activity participants any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the activity content. The intent of this policy is identifying potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. It remains for the participants to determine whether the speaker’s outside interests reflect a possible bias in either the exposition or the conclusions presented.

Commercial Support: No commercial support was received for this activity.

Software Requirements: VuMedi Webinars supports the following web browsers (with enabled JavaScript™): Internet Explorer® versions 6.0, 7.0, 8.0, Mozilla Firefox versions 1.0, 2.0, 3.0, and Safari for Mac. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Adobe Acrobat®, Adobe® Flash Player, Microsoft® Office PowerPoint, and Microsoft® Office Word.These activities will be marked as such and will provide links to the required software.

Copyright: Any and/or all materials are for the exclusive use of the faculty and participants of the live activity. Any copying, duplicating or reproducing of any and/or all materials by electronic, mechanical or other means for any purpose other than this enduring activity is strictly prohibited without prior written consent of the author of those materials.

Policy on Privacy and Confidentiality: For more information regarding VuMedi's Policy on Privacy and Confidentiality, please visit http://www.vumedi.com/pages/privacy/

To Contact our Accredited Provider: Ellen P. Seaback, CMP, CAE, CHCP
Executive Director
Office of Continuing Medical Education
UC Irvine Health School of Medicine
Irvine, California
eseaback@uci.edu
949.824.1150
http://www.meded.uci.edu/CME/

For questions regarding this activity, please contact VuMedi: cme@vumedi.com


7 Comments
Login to view comments. Click here to Login